Management and outcome of central precocious puberty

Partsch, Carl-Joachim; Heger, Sabine; Sippell, Wolfgang G.

doi:10.1046/j.0300-0664.2001.01490.x

Cited by 172 publications

(146 citation statements)

References 247 publications

Supporting

Mentioning

124

Contrasting

Unclassified

Order By: Relevance

“…It is estimated that precocious puberty affects between 1 in 5000 and 1 in 10 000 children and a high female to male ratio (37). There is consensus, at least in Europe, on the chronological age points below which onset of puberty is considered to be precocious in either sex.…”

Section: Discussionmentioning

confidence: 99%

The use of GnRH agonists in precocious puberty

Mul¹,

Hughes

2008

European Journal of Endocrinology

View full text Add to dashboard Cite

In this review several aspects of gonadotrophin releasing hormone agonists (GnRHa) treatment in central precocious puberty (CPP) are highlighed. These include issues of the definition of precocity, assessment of CPP and thelarche variants. Indications for treatment with GnRH agonists are discussed, not only in CPP but also in children with other reasons to suppress central activation, e.g. adopted or developmental retardation. Finally, outcome data are summarized, both on growth and psychosocial parameters.European Journal of Endocrinology 159 S3-S8

show abstract

Section: Discussionmentioning

confidence: 99%

The use of GnRH agonists in precocious puberty

Mul¹,

Hughes

2008

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Precocious puberty (PP) is defined as the onset of puberty before the age of eight in girls and nine in boys, mainly because of the precocious activation of the gonadotropic axis, which induces several somatic and psychological modifications (1). PP results in an increasing growth rate and rapid acceleration of bone maturation, which leads to the early fusion of epiphyseal and eventually adult short stature (2).…”

mentioning

confidence: 99%

“…CPP is gonadotropin-dependent early maturation and results primarily from activation of HPGA, whereas PPP is gonadotropin-independent; the causes of PPP include both endogenous sources such as gonadal tumors, adrenal tumors, and congenital disorders and exposure to exogenous steroids (5). Gonadotropin-releasing hormone (GnRH), which is produced in the hypothalamus and acts on the pituitary gland, stimulates the pulsatile production and release of gonadotropins including luteinizing hormones (LH) and follicle-stimulating hormones (FSH) to maintain normal reproductive functions (1). Correct diagnosis of the etiology of sexual precocity is critical, because treatment of patients with PPP is different from those with CPP, and some PPP can secondarily evolve into CPP (6).…”

mentioning

confidence: 99%

“…Puberty, the primary regulator of the reproductive process in vertebrates, is a complex biological process affected by systemic and environmental factors such as activation of the hypothalamic-pituitary-gonadal axis (HPGA) 1 (1). Precocious puberty (PP) is defined as the onset of puberty before the age of eight in girls and nine in boys, mainly because of the precocious activation of the gonadotropic axis, which induces several somatic and psychological modifications (1).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Urinary Metabolite Markers of Precocious Puberty

Пин

Zhang

et al. 2012

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

The incidence of precocious puberty (PP, the appearance of signs of pubertal development at an abnormally early age), is rapidly rising, concurrent with changes of diet, lifestyles, and social environment. The current diagnostic methods are based on a hormone (gonadotropin-releasing hormone) stimulation test, which is costly, time-consuming, and uncomfortable for patients. The lack of molecular biomarkers to support simple laboratory tests, such as a blood or urine test, has been a long standing bottleneck in the clinical diagnosis and evaluation of PP. Here we report a metabolomic study using an ultra performance liquid chromatography-quadrupole time of flight mass spectrometry and gas chromatography-time of flight mass spectrometry. Urine metabolites from 163 individuals were profiled, and the metabolic alterations were analyzed after treatment of central precocious puberty (CPP) with triptorelin depot. A panel of biomarkers selected from >70 differentially expressed urinary metabolites by receiver operating characteristic and logistic regression analysis provided excellent predictive power with high sensitivity and specificity for PP. The altered metabolic profile of the PP patients was characterized by three major perturbed metabolic pathways: catecholamine, serotonin metabolism, and tricarboxylic acid cycle, presumably resulting from activation of the sympathetic nervous system and the hypothalamic-pituitary-gonadal axis. Treatment with triptorelin depot was able to normalize these three altered pathways. Additionally, significant changes in the urine levels of 4-hydroxyphenylacetic acid, 5-hydroxyindoleacetic acid, indoleacetic acid, 5-hydroxytryptophan, and 5-hydroxykynurenamine in the CPP group suggest that the development of CPP condi-

show abstract

“…Embora a ocorrência de PPC em crianças do sexo masculino seja reconhecidamente baixa, observou-se na presente pesquisa uma razão excessivamente elevada entre o sexo feminino e o masculino, de 37:1, bastante acima da observada em revisão da literatura internacional, que encontrou razões situadas entre 3:1 e 23:1 (18) . Essa observação sugere um possível desconhecimento por parte dos pais das crianças quanto ao momento inicial do ingresso da puberdade para as crianças do sexo masculino, o que poderia implicar em uma menor procura por atendimento especializado para crianças do sexo masculino com puberdade precoce.…”

Section: Discussionunclassified